Regeneron Pharmaceuticals (REGN) Construction in Progress (2013 - 2017)

Regeneron Pharmaceuticals has reported Construction in Progress for 5 years, with the latest figure at $408.9 million in Q4 2017.

• For the quarter ending Q4 2017, Construction in Progress rose 28.2% year-over-year to $408.9 million; the trailing twelve-month figure through Dec 2017 stood at $408.9 million (up 28.2% YoY), and the FY2017 full-year result was $408.9 million, up 28.2% from the prior year.
• Construction in Progress for Q4 2017 stood at $408.9 million, up from $318.9 million in the prior quarter.
• The five-year high for Construction in Progress was $579.8 million in Q4 2015, with the low at $142.4 million in Q4 2013.
• Average Construction in Progress over 5 years is $384.4 million, with a median of $408.9 million recorded in 2017.
• Year-over-year, Construction in Progress soared 231.69% in 2014 and plunged 45.0% in 2016.
• Tracing REGN's Construction in Progress over 5 years: stood at $142.4 million in 2013, then soared by 231.69% to $472.2 million in 2014, then advanced by 22.79% to $579.8 million in 2015, then sank by 45.0% to $318.9 million in 2016, then climbed by 28.2% to $408.9 million in 2017.
• The last three Construction in Progress figures came in at $408.9 million (Q4 2017), $318.9 million (Q4 2016), and $579.8 million (Q4 2015), per Business Quant data.

Peer Comparison